(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/194586 A3

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/7088* (2006.01)

(21) International Application Number:
PCT/EP2023/059279

(22) International Filing Date:
06 April 2023 (06.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
22167394.0 08 April 2022 (08.04.2022) EP

(71) Applicants: **SECARNA PHARMACEUTICALS GMBH & CO. KG** [DE/DE]; Bismarckstr. 7, 35037 Marburg (DE). **SCINEURO THERAPEUTICS INC.** [US/US]; 9605 Medical Center Drive, Suite 230, Rockville, Maryland 20850 (US).

(72) Inventors: **DE LOS REYES, Marta Lucia**; c/o Bismarckstr. 7, 35037 Marburg (DE). **KLAR, Richard**; c/o Bismarckstr. 7, 35037 Marburg (DE). **MICHEL, Sven**; c/o Bismarckstr. 7, 35037 Marburg (DE). **JASCHINSKI, Frank**; c/o Bismarckstr. 7, 35037 Marburg (DE). **RIERA, Irene**; c/o Bismarckstr. 7, 35037 Marburg (DE). **LI, Min**; c/o 9605 Medical Center Drive, Suite 230, Rockville, Maryland 20850 (US). **ZEMBRZYCKI, Andreas**; c/o 9605 Medical Center Drive, Suite 230, Rockville, Maryland 20850 (US). **SU, Dai-Shi**; c/o 9605 Medical Center Drive, Suite 230, Rockville, Maryland 20850 (US).

(74) Agent: **WITMANS, H.A.**; V.O., P.O. Box 87930, 2508 DH Den Haag (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
23 November 2023 (23.11.2023)

WO 2023/194586 A3

(54) Title: OLIGONUCLEOTIDE FOR REDUCING THE EXPRESSION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) AND ITS USE FOR PREVENTING AND/OR TREATING HUMAN DISEASES

(57) Abstract: The present invention refers to an oligonucleotide comprising 10 to 25 nucleotides, at least one nucleotide having a modification, wherein the oligonucleotide hybridizes with a transcript or an mRNA of leucine-rich repeat kinase 2 (LRRK2) of SEQ ID NO.1 and/or with pre-mRNA of LRRK2 of SEQ ID NO.2 and/or a fragment thereof. The invention further refers to a pharmaceutical composition comprising such oligonucleotide, and the use of the oligonucleotide and pharmaceutical composition, respectively, for use in method of preventing and/or treating a human disease.